参考文献/References:
[1] Riaz A, Huang Y, Johansson S. G-Protein-Coupled lysophosphatidic acid receptors and their regulation of AKT signaling[J]. International Journal of Molecular Sciences, 2016, 17(2): 215.
[2] Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions[J]. Annual Review of Pharmacology and Toxicology, 2010, 50:157-186.
[3] LIN M-e,d r herr, J CHUN L A. Receptors:signaling properties and disease relevance[J]. Prostaglandins & Other Lipid Mediators, 2010, 91(3/4): 130-138.
[4] Yung YC, Stoddard NC, Mirendil H, et al. Lysophosphatidic acid signaling in the nervous system[J]. Neuron, 2015, 85(4): 669-682.
[5] Yung YC, Chun J. LPA receptor signaling:pharmacology,physiology,and pathophysiology[J]. Journal of Lipid Research, 2014, 55(7): 1192-1214.
[6] Hecht, HJ. Ventricular zone gene-1(vzg-1)encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex[J]. Journal of Cell Biology, 1996, 135(4): 1071-1083.
[7] Lopane C, Agosti P, Gigante I, et al. Implications of the lysophosphatidic acid signaling axis in liver cancer[J]. Biochimica et Biophysica Acta-Reviews on Cancer, 2017, 1868(1): 277-282.
[8] Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system[J]. Biochimica et Biophysica acta, 2013, 1831(1): 20-32.
[9] Goldshmit Y, Munro K, Leong SY, et al. LPA receptor expression in the central nervous system in health and following injury[J]. Cell and Tissue Research, 2010, 341(1): 23-32.
[10] Contos JJ, Fukushima N, Weiner JA, et al. Requirement for the Ip(A1)lysophosphatidic acid receptor gene in normal suckling behavior[J]. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97(24): 13384-13389.
[11] Skoura A, Hla T. Lysophospholipid receptors in vertebrate development,physiology,and pathology[Z], 2009: S293-S298.
[12] Frugier T, Crombie D, Conquest A, et al. Modulation of LPA receptor expression in the human brain following neurotrauma[J]. Cellular and Molecular Neurobiology, 2011, 31(4): 569-577.
[13] Im, SD. Molecular cloning and characterization of a lysophosphatidic acid receptor,Edg-7,expressed in prostate[J]. Molecular Pharmacology, 2000, 57(4): 753-759.
[14] YE Xiaoqin, Hama K, Contos JJ, et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing[J]. Nature, 2005, 435(738): 104-108.
[15] Araki, M. Inhibitory effects of lysophosphatidic acid receptor-5 on cellular functions of sarcoma cells[J]. Growth Factors, 2014, 32(3/4): 117-122.
[16] Ohuchi H, Hamada A, Matsuda H, et al. Expression patterns of the lysophospholipid receptor genes during mouse early development[J]. Developmental Dynamics, 2008, 237(11): 3280-3294.
[17] Choi JW, Chun J. Biological roles of lysophospholipid receptors revealed by genetic null mice:an update[J]. Biochimica et Biophysica acta, 2008, 1781(9): 531-539.
[18] Lee M. P2Y5 is a G(alpha)i,G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion[J]. American Journal of Physiology. Gastrointestinal and Liver Physiology, 2009, 297(4): G641-G654.
[19] Geach TJ, Faas L, Devader CA, et al. An essential role for LPA signalling in telencephalon development[J]. Development, 2014, 141(4): 940-949.
[20] Konakazawa, M. The effect of cyclic phosphatidic acid on the proliferation and differentiation of mouse cerebellar granule precursor cells during cerebellar development[Z], 2015: 28-37.
[21] Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic Acid signaling[J]. Biomolecules & Therapeutics, 2015, 23(1): 1-11.
[22] Velasco M, O'Sullivan C, Sheridan GK. Lysophosphatidic acid receptors(LPARs): Potential targets for the treatment of neuropathic pain[J]. Neuropharmacology, 2017,113(PtB):608-617.
[23] Weiner JA, Fukushima N, Contos JJ, et al. Regulation of schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling[J]. Journal of Neuroscience, 2001, 21(18): 7069-7078.
[24] Inoue, M. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling[J]. Nature Medicine, 2004, 10(7): 712-718.
[25] Yan H, Lu D, and Rivkees SA. Lysophosphatidic acid regulates the proliferation and migration of olfactory ensheathing cells in vitro[J]. Glia, 2003,44(1):26-36.
[26] Furuta D, Yamane M, Tsujiuchi TA, et al. Lysophosphatidic acid induces neurite branch formation through LPA(3)[J]. Molecular and Cellular Neuroscience, 2012, 50(1): 21-34.
[27] Lee CW, Rivera R, Dubin AE, et al. LPA(4)/GPR23 is a lysophosphatidic acid(LPA)receptor utilizing G(s)-, G(q)/G(i)-mediated Calcium signaling and G(12/13)-mediated Rho activation[J]. Journal of Biological Chemistry, 2007, 282(7): 4310-4317.
[28] Yanagida K, Ishii S. Non-Edg family LPA receptors: the cutting edge of LPA research[J]. Journal of Biochemistry, 2011, 150(3): 223-232.
[29] Lee Z, Cheng CT, Zhang H, et al. Role of LPA4/p2y9/GPR23 in negative regulation of cell motility[J]. Molecular Biology of the Cell, 2008, 19(12): 5435-5445.
[30] Yanagida K, Kurikawa Y, Shimizu T, et al. Current progress in non-Edg family LPA receptor research[J]. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, 2013, 1831(1, SI): 33-41.
[31] Yamane MF, Fukushima N. Lysophosphatidic acid influences initial neuronal polarity establishment[J]. Neuroscience Letters, 2010, 480(2): 154-157.
[32] Li ZG, YU Zhan-cai, Wang Dao-zhen, et al. Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases[J]. Neurological Research, 2008, 30(4): 366-369.
[33] Yung YC. Lysophosphatidic acid signaling may initiate fetal hydrocephalus[J]. Sci Transl Med, 2011,3(99):99ra87.
[34] Corcoran A,O'connor JJ. Hypoxia-inducible factor signalling mechanisms in the central nervous system[J]. Acta Physiol(Oxf),2013,208(4):298-310.
[35] Hansson GK, Hermansson A. The immune system in atherosclerosis[J]. Nature Immunology, 2011, 12(3): 204-212.
[36] Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options[J]. Nature Medicine, 2011, 17(11): 1410-1422.
[37] LIN Chi-lou, Chen CN, LIN Po-wei, et al. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA(1)and LPA(3)[J]. Biochemical and Biophysical Research Communications, 2007, 363(4): 1001-1008.
[38] Bot M, Bot I, Lopez-vales R, et al. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation[J]. The American Journal of Pathology, 2010, 176(6): 3073-3084.
[39] Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways[J]. Lancet Neurology, 2010, 9(7): 727-739.
[40] Dominguez-pinos D, DM. Ependymal denudation and alterations of the subventricular zone occur in human fetuses with a moderate communicating hydrocephalus[J]. Journal of Neuropathology and Experimental Neurology, 2005, 64(7): 595-604.
[41] Balood M, Zahednasab H, Siroos BA, et al. Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis[J]. Human Immunology, 2014, 75(5): 411-413.
[42] Goetzl EJ, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax[J]. Journal of Immunology, 1999, 162(4): 2049-2056.
[43] Bowden NA. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia[J]. Schizophrenia Research, 2006, 82(2/3): 175-183.
[44] Harrison MS. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease[J]. Molecular and Cellular Neuroscience, 2003, 24(4): 1170-1179.